ENYO Pharma

About:

ENYO Pharma is a biopharmaceutical company based in Lyon, France.

Website: http://www.enyopharma.com/

Twitter/X: enyopharma

Top Investors: Andera Partners, Bpifrance, OrbiMed, Sofinnova Investments, Morningside Venture Investments

Description:

ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public). The company is based in the Infectiology Center of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team and the BSL4 laboratory Inserm-Jean Mérieux. ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules. The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials.

Total Funding Amount:

103M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Lyon, Rhone-Alpes, France

Founded Date:

2014-01-01

Contact Email:

contact(AT)enyopharma.com

Founders:

Benoit Chassey, Jacky Vonderscher, Jean-Jacques Garaud, Laurene Schicklin, Patrice Andre, Vincent Lotteau

Number of Employees:

11-50

Last Funding Date:

2024-01-03

IPO Status:

Private

Industries:

© 2025 bioDAO.ai